【レポートの概要（一部）】
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 15
2 Introduction 16
2.1 Immunochemistry Analyzers Overview 16
3 Products under Development 18
3.1 Immunochemistry Analyzers – Pipeline Products by Stage of Development 18
3.2 Immunochemistry Analyzers – Pipeline Products by Segment 19
3.3 Immunochemistry Analyzers – Pipeline Products by Territory 20
3.4 Immunochemistry Analyzers – Pipeline Products by Regulatory Path 22
3.5 Immunochemistry Analyzers – Pipeline Products by Estimated Approval Date 23
3.6 Immunochemistry Analyzers – Ongoing Clinical Trials 24
4 Immunochemistry Analyzers – Pipeline Products under Development by Companies 25
4.1 Immunochemistry Analyzers Companies – Pipeline Products by Stage of Development 25
4.2 Immunochemistry Analyzers – Pipeline Products by Stage of Development 29
5 Immunochemistry Analyzers Companies and Product Overview 33
5.1 Acreo Swedish ICT AB Company Overview 33
5.1.1 Acreo Swedish ICT AB Pipeline Products & Ongoing Clinical Trials Overview 33
5.2 AESKU.Diagnostics GmbH & Co. KG Company Overview 34
5.2.1 AESKU.Diagnostics GmbH & Co. KG Pipeline Products & Ongoing Clinical Trials Overview 34
5.3 Akonni Biosystems, Inc. Company Overview 36
5.3.1 Akonni Biosystems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 36
5.4 Arcxis Biotechnologies Inc. Company Overview 38
5.4.1 Arcxis Biotechnologies Inc. Pipeline Products & Ongoing Clinical Trials Overview 38
5.5 Assay Dynamics, LLC Company Overview 39
5.5.1 Assay Dynamics, LLC Pipeline Products & Ongoing Clinical Trials Overview 39
5.6 Atonomics A/S Company Overview 40
5.6.1 Atonomics A/S Pipeline Products & Ongoing Clinical Trials Overview 40
5.7 Beckman Coulter, Inc. Company Overview 42
5.7.1 Beckman Coulter, Inc. Pipeline Products & Ongoing Clinical Trials Overview 42
5.8 BioMedomics, Inc Company Overview 44
5.8.1 BioMedomics, Inc Pipeline Products & Ongoing Clinical Trials Overview 44
5.9 BioNanovations Corporation Company Overview 47
5.9.1 BioNanovations Corporation Pipeline Products & Ongoing Clinical Trials Overview 47
5.10 BioSIMS Company Overview 48
5.10.1 BioSIMS Pipeline Products & Ongoing Clinical Trials Overview 48
5.11 Boston University Company Overview 49
5.11.1 Boston University Pipeline Products & Ongoing Clinical Trials Overview 49
5.12 Canon U.S.A., Inc. Company Overview 51
5.12.1 Canon U.S.A., Inc. Pipeline Products & Ongoing Clinical Trials Overview 51
5.13 CardioGenics Inc. Company Overview 52
5.13.1 CardioGenics Inc. Pipeline Products & Ongoing Clinical Trials Overview 52
5.14 Celsee Diagnostics, Inc. Company Overview 54
5.14.1 Celsee Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 54
5.15 Cepheid Company Overview 55
5.15.1 Cepheid Pipeline Products & Ongoing Clinical Trials Overview 55
5.16 China Medical Technologies, Inc. Company Overview 58
5.16.1 China Medical Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 58
5.17 ChipCare Corp Company Overview 61
5.17.1 ChipCare Corp Pipeline Products & Ongoing Clinical Trials Overview 61
5.18 Clearbridge BioLoc Pte Ltd Company Overview 65
5.18.1 Clearbridge BioLoc Pte Ltd Pipeline Products & Ongoing Clinical Trials Overview 65
5.19 Corgenix Medical Corporation Company Overview 66
5.19.1 Corgenix Medical Corporation Pipeline Products & Ongoing Clinical Trials Overview 66
5.20 Courtagen Life Sciences, Inc. Company Overview 68
5.20.1 Courtagen Life Sciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview 68
5.21 Curetis N.V. Company Overview 69
5.21.1 Curetis N.V. Pipeline Products & Ongoing Clinical Trials Overview 69
5.22 Denator AB Company Overview 78
5.22.1 Denator AB Pipeline Products & Ongoing Clinical Trials Overview 78
5.23 DiaSorin S.p.A Company Overview 79
5.23.1 DiaSorin S.p.A Pipeline Products & Ongoing Clinical Trials Overview 79
5.24 Dyamed Biotech Pte Ltd Company Overview 81
5.24.1 Dyamed Biotech Pte Ltd Pipeline Products & Ongoing Clinical Trials Overview 81
5.25 Dynex Technologies Company Overview 82
5.25.1 Dynex Technologies Pipeline Products & Ongoing Clinical Trials Overview 82
5.26 EKF Diagnostics Holdings Plc Company Overview 83
5.26.1 EKF Diagnostics Holdings Plc Pipeline Products & Ongoing Clinical Trials Overview 83
5.27 Enigma Diagnostics Limited Company Overview 85
5.27.1 Enigma Diagnostics Limited Pipeline Products & Ongoing Clinical Trials Overview 85
5.28 F Cubed LLC Company Overview 86
5.28.1 F Cubed LLC Pipeline Products & Ongoing Clinical Trials Overview 86
5.29 Firalis SAS Company Overview 87
5.29.1 Firalis SAS Pipeline Products & Ongoing Clinical Trials Overview 87
5.30 First Light Biosciences, Inc. Company Overview 89
5.30.1 First Light Biosciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview 89
5.31 Florida State University Company Overview 90
5.31.1 Florida State University Pipeline Products & Ongoing Clinical Trials Overview 90
5.32 GenePOC Inc. Company Overview 91
5.32.1 GenePOC Inc. Pipeline Products & Ongoing Clinical Trials Overview 91
5.33 Genera Biosystems Limited Company Overview 93
5.33.1 Genera Biosystems Limited Pipeline Products & Ongoing Clinical Trials Overview 93
5.34 Genevo Biosystems Pte Ltd Company Overview 95
5.34.1 Genevo Biosystems Pte Ltd Pipeline Products & Ongoing Clinical Trials Overview 95
5.35 GenMark Diagnostics, Inc. Company Overview 96
5.35.1 GenMark Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 96
5.36 Global Solutions for Infectious Diseases Company Overview 98
5.36.1 Global Solutions for Infectious Diseases Pipeline Products & Ongoing Clinical Trials Overview 98
5.37 GNA Biosolutions GmbH Company Overview 100
5.37.1 GNA Biosolutions GmbH Pipeline Products & Ongoing Clinical Trials Overview 100
5.38 Harvard University Company Overview 102
5.38.1 Harvard University Pipeline Products & Ongoing Clinical Trials Overview 102
5.39 HeatFlow Technologies, Inc. Company Overview 103
5.39.1 HeatFlow Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 103
5.40 Hologic, Inc. Company Overview 104
5.40.1 Hologic, Inc. Pipeline Products & Ongoing Clinical Trials Overview 104
5.41 HTG Molecular Diagnostics, Inc. Company Overview 106
5.41.1 HTG Molecular Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 106
5.42 Immunexpress Pty Ltd Company Overview 108
5.42.1 Immunexpress Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 108
5.43 Immunodiagnostic Systems Holdings plc Company Overview 109
5.43.1 Immunodiagnostic Systems Holdings plc Pipeline Products & Ongoing Clinical Trials Overview 109
5.44 Intelligent Fingerprinting Ltd Company Overview 110
5.44.1 Intelligent Fingerprinting Ltd Pipeline Products & Ongoing Clinical Trials Overview 110
5.45 Johnson & Johnson Company Overview 111
5.45.1 Johnson & Johnson Pipeline Products & Ongoing Clinical Trials Overview 111
5.46 LaserGen, Inc. Company Overview 114
5.46.1 LaserGen, Inc. Pipeline Products & Ongoing Clinical Trials Overview 114
5.47 Lucerna, Inc. Company Overview 115
5.47.1 Lucerna, Inc. Pipeline Products & Ongoing Clinical Trials Overview 115
5.48 Magellan Diagnostics, Inc. Company Overview 116
5.48.1 Magellan Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 116
5.49 Magnisense SAS Company Overview 117
5.49.1 Magnisense SAS Pipeline Products & Ongoing Clinical Trials Overview 117
5.50 MAST GROUP Ltd. Company Overview 118
5.50.1 MAST GROUP Ltd. Pipeline Products & Ongoing Clinical Trials Overview 118
5.51 Maxygen-mobile DNA tests Company Overview 119
5.51.1 Maxygen-mobile DNA tests Pipeline Products & Ongoing Clinical Trials Overview 119
5.52 mBio Diagnostics, Inc. Company Overview 120
5.52.1 mBio Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 120
5.53 McKesson Corporation Company Overview 123
5.53.1 McKesson Corporation Pipeline Products & Ongoing Clinical Trials Overview 123
5.54 MedNostic Technologies, LLC Company Overview 125
5.54.1 MedNostic Technologies, LLC Pipeline Products & Ongoing Clinical Trials Overview 125
5.55 Mindray Medical International Limited Company Overview 126
5.55.1 Mindray Medical International Limited Pipeline Products & Ongoing Clinical Trials Overview 126
5.56 Mobidiag Ltd. Company Overview 128
5.56.1 Mobidiag Ltd. Pipeline Products & Ongoing Clinical Trials Overview 128
5.57 NanoLab, Inc. Company Overview 130
5.57.1 NanoLab, Inc. Pipeline Products & Ongoing Clinical Trials Overview 130
5.58 Nanosphere, Inc. Company Overview 132
5.58.1 Nanosphere, Inc. Pipeline Products & Ongoing Clinical Trials Overview 132
5.59 Next Dimension Technologies, Inc. Company Overview 134
5.59.1 Next Dimension Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 134
5.60 NorthShore University Health System Company Overview 135
5.60.1 NorthShore University Health System Pipeline Products & Ongoing Clinical Trials Overview 135
5.61 OncoGenesis Company Overview 136
5.61.1 OncoGenesis Pipeline Products & Ongoing Clinical Trials Overview 136
5.62 Optidet Diagnostics Ltd Company Overview 137
5.62.1 Optidet Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 137
5.63 Optofluidics, Inc. Company Overview 138
5.63.1 Optofluidics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 138
5.64 Ostendum R&D BV Company Overview 139
5.64.1 Ostendum R&D BV Pipeline Products & Ongoing Clinical Trials Overview 139
5.65 Polymedco CDP, LLC Company Overview 140
5.65.1 Polymedco CDP, LLC Pipeline Products & Ongoing Clinical Trials Overview 140
5.66 Protomex Life Sciences Company Overview 141
5.66.1 Protomex Life Sciences Pipeline Products & Ongoing Clinical Trials Overview 141
5.67 Qiagen N.V. Company Overview 142
5.67.1 Qiagen N.V. Pipeline Products & Ongoing Clinical Trials Overview 142
5.68 Quanterix Corporation Company Overview 148
5.68.1 Quanterix Corporation Pipeline Products & Ongoing Clinical Trials Overview 148
5.69 QuantuMDx Group Limited Company Overview 149
5.69.1 QuantuMDx Group Limited Pipeline Products & Ongoing Clinical Trials Overview 149
5.70 Quidel Corporation Company Overview 150
5.70.1 Quidel Corporation Pipeline Products & Ongoing Clinical Trials Overview 150
5.71 Radisens Diagnostics Limited Company Overview 152
5.71.1 Radisens Diagnostics Limited Pipeline Products & Ongoing Clinical Trials Overview 152
5.72 Raman Diagnostics Limited Company Overview 154
5.72.1 Raman Diagnostics Limited Pipeline Products & Ongoing Clinical Trials Overview 154
5.73 Rapid Biosensor Systems Company Overview 155
5.73.1 Rapid Biosensor Systems Pipeline Products & Ongoing Clinical Trials Overview 155
5.74 Rapid Diagnostek, Inc. Company Overview 156
5.74.1 Rapid Diagnostek, Inc. Pipeline Products & Ongoing Clinical Trials Overview 156
5.75 Siemens Healthcare Diagnostics Inc. Company Overview 157
5.75.1 Siemens Healthcare Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview 157
5.76 Siloam Biosciences, Inc. Company Overview 159
5.76.1 Siloam Biosciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview 159
5.77 Singulex, Inc. Company Overview 160
5.77.1 Singulex, Inc. Pipeline Products & Ongoing Clinical Trials Overview 160
5.78 Spire Corporation Company Overview 162
5.78.1 Spire Corporation Pipeline Products & Ongoing Clinical Trials Overview 162
5.79 Stat-Diagnostica & Innovation, S.L. Company Overview 164
5.79.1 Stat-Diagnostica & Innovation, S.L. Pipeline Products & Ongoing Clinical Trials Overview 164
5.80 STRATEC Molecular GmbH Company Overview 165
5.80.1 STRATEC Molecular GmbH Pipeline Products & Ongoing Clinical Trials Overview 165
5.81 Sysmex Corporation Company Overview 167
5.81.1 Sysmex Corporation Pipeline Products & Ongoing Clinical Trials Overview 167
5.82 Tecan Group Ltd Company Overview 169
5.82.1 Tecan Group Ltd Pipeline Products & Ongoing Clinical Trials Overview 169
5.83 Techcomp (Holdings) Limited Company Overview 170
5.83.1 Techcomp (Holdings) Limited Pipeline Products & Ongoing Clinical Trials Overview 170
5.84 The Palo Alto Research Center Company Overview 172
5.84.1 The Palo Alto Research Center Pipeline Products & Ongoing Clinical Trials Overview 172
5.85 TrovaGene, Inc. Company Overview 173
5.85.1 TrovaGene, Inc. Pipeline Products & Ongoing Clinical Trials Overview 173
5.86 Tyncbest Biotechnology Company Overview 175
5.86.1 Tyncbest Biotechnology Pipeline Products & Ongoing Clinical Trials Overview 175
5.87 University of California, Davis Company Overview 177
5.87.1 University of California, Davis Pipeline Products & Ongoing Clinical Trials Overview 177
5.88 University of California, San Diego Company Overview 178
5.88.1 University of California, San Diego Pipeline Products & Ongoing Clinical Trials Overview 178
5.89 University of Michigan Company Overview 180
5.89.1 University of Michigan Pipeline Products & Ongoing Clinical Trials Overview 180
5.90 University of Michigan Pediatric Device Consortium Company Overview 181
5.90.1 University of Michigan Pediatric Device Consortium Pipeline Products & Ongoing Clinical Trials Overview 181
5.91 Wellstat Diagnostics, LLC Company Overview 182
5.91.1 Wellstat Diagnostics, LLC Pipeline Products & Ongoing Clinical Trials Overview 182
5.92 Xanthostat Diagnostics, Inc. Company Overview 184
5.92.1 Xanthostat Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 184
5.93 ZIN Technologies, Inc. Company Overview 185
5.93.1 ZIN Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 185
6 Immunochemistry Analyzers- Recent Developments 186
7 Appendix 262
7.1 Methodology 262
7.2 About GlobalData 264
7.3 Contact Us 265
7.4 Disclaimer 265
【レポート販売概要】
■ タイトル：世界の免疫化学分析装置開発動向：医療機器パイプライン分析2015■ 英文：Immunochemistry Analyzers - Medical Devices Pipeline Assessment, 2015
■ 発行日：2016年1月5日
■ 調査会社：GlobalData
■ 商品コード：GDME0147EPD
■ 調査対象地域：グローバル
- 世界のVLC（可視光通信）/Li-Fi/FSO（自由空間光通信）市場：トランスミッタ、レシーバー、モジュレータ、復調器The VLC and FSO market report analyses the ecosystem for both the technologies. The market has been segmented by components which include: transmitter, receiver, modulators and demodulators, and others. By application it includes: automotive, healthcare, aerospace, underwater communication, and others. FSO technology application segment include: terrestrial application, mobile application, and sat …
- 燐酸塩、リン酸塩およびポリリン酸塩市場：フランスThis report is a comprehensive research of phosphites, phosphates and polyphosphates industry in France. The first two chapters of the report feature the country profile by giving general information on France and by thoroughly studying its economic state, (including key macroeconomic indicators and their development trends). The third chapter covers common business procedures in the country: from …
- 医療レポート：Dermatophytic Onychomycosis-疫学予測（～2022）EpiCast Report: Dermatophytic Onychomycosis - Epidemiology Forecast to 2022 Summary Dermatophytic onychomycosis (DO) is an infection of the nail fold or nail plate with dermatophytes, a type of fungus, especially Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton flocossom (Sterry et al., 2006). DO begins as a white/yellow spot under the tip of the nail. As the infection spreads …
- 世界の非在来型石油・ガス開発向け化学物質市場予測：シェールガス、シェール油、タイトガスおよびCBMのための破砕液添加剤Chemicals used in the development of unconventional oil and gas resources are an essential element for ensuring the adequate preparation, fracturing, completion and integrity of an unconventional well. Pumped into the wellbore at different times during the drilling and completion process, the chemicals have a variety of purposes, from initiating cracks, to distributing proppant and protecting tubu …
- 世界の内視鏡検査装置市場動向及び予測（～2018）Over the years, the endoscopy equipment market, which comprises endoscopes and visualization equipment, has witnessed various technological advancements. These advancements have led to a growth in the number of application areas of endoscopic equipment. Endoscopy devices are used in laparoscopy, arthroscopy, bronchoscopy, gastrointestinal endoscopy, urology, gynecology, and neuroendoscopy, among o …
- 世界のテレコム市場動向－M2M、クラウド・コンピューティング、ビッグデータ、Wi-Fiなどによる市場変化：Global Telecoms – Industry Transformation with M2M, Cloud Computing, Big Data, Wi-Fi and New SpectrumExciting developments for increasingly vital telecoms industryThere is no doubt that the next ten years will bring further exciting developments to the increasingly vital telecommunications industry. The foundations for change are already well in motion and the continuing deployment of high-speed broadband and 4G technology will provide the infrastructure to ignite the new innovations and revoluti …
- Relapsed Chronic Lymphocytic Leukemia (慢性リンパ性白血病)：グローバル臨床試験動向（2014年上半期）Relapsed Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Relapsed Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2014" provides data on the Relapsed Chronic Lymphocytic Leukemia (CLL) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Relapsed …
- 横紋筋肉腫(Rhabdomyosarcoma)：治療薬開発パイプライン動向（2015年上半期版）Rhabdomyosarcoma - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Rhabdomyosarcoma - Pipeline Review, H1 2015’, provides an overview of the Rhabdomyosarcoma’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Rhabdomyosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of …
- CMOの新しい責任：内部・外部モバイルリソース管理（New Responsibilities for the Chief Mobile Officer: Managing Internal Mobile Resources for Employees as well as External Mobile Resources for Customers）It wasn't too long ago that enterprise IT was primarily focused on their local area network serving the computing requirements of their employees while 'tolerating' the few people who were issued laptops, so they could be productive while on the road. Enterprise mobility was a subset of 'true IT management' - something that was dealt with as an aggravation rather than an asset. This report focuses …
- 量子暗号の世界市場予測（～2022年）：ハードウェア、ソフトウェア“Quantum cryptography market projected to grow at a CAGR of 27.0% during the forecast period”The global quantum cryptography market size is expected to grow from USD 285.7 million in 2017 to USD 943.7 million by 2022, at a CAGR of 27.0%. With the growing incident of cyber-attacks, increasing data security and privacy concerns, rising adoption of cloud storage and computing technologies, and evolvi …
- 宝くじの世界市場2020-2024Global Lottery Market 2020-2024 Technavio has been monitoring the lottery and it is poised to grow by USD 220.52 billion during 2020-2024, progressing at a CAGR of 10% during the forecast period. Our reports on lottery provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-dat …
- 肺動脈高血圧（PAH）の世界市場分析：薬の問題別（プロスタサイクリンおよびプロスタサイクリンアナログ、可溶性グアニル酸シクラーゼ（SGC）刺激薬、エンドセリン受容体アンタゴニスト（ERA）、ホスホジエステラーゼ5（PDE-5）、セグメント予測、2014-2025The Pulmonary Arterial Hypertension (PAH) market is expected to reach USD 8.7 billion by 2025, according to the new report by Grand View Research, Inc. Incidents of PAH, increasing geriatric population, and government support to develop orphan drugs are key driving factors. Cumulatively, the cases of PAH are in the range of 100,000 to 200,000 per year. However, in the past few years, the prevalenc …
- 世界の冷蔵デリ食品市場動向（2012-2016）TechNavio's analysts forecast the Global Chilled and Deli Food market to grow at a CAGR of 2.71 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in demand for convenience in food products. The Global Chilled and Deli Food market has also been witnessing the increasing private label brands. However, the highly fragmented market could pose …
- PharmaSphere: Early-Stage Technology Transfer Collaborations – Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical IndustryPharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical Industry Summary "PharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical Industry" report provides a cross-section of major licensing deals between mid t …
- 高速鉄道（HSR）向け複合材の世界市場：ガラス複合材、炭素複合材About Composites for HSR HSR is a railway transportation system that runs at speeds of more than 150 mph and is currently considered one of the fastest, most environment-friendly, and safest modes of transport across the globe. HSR systems, since their advent, have been an integral part of the transportation sector in developed countries in Europe and APAC. These systems provide the advantages of …
